Investment
Features
FeesSafety
Academy
More
Pluang+

Rising US debt and deficits boost Bitcoin's appeal as a long-term investment, says BlackRock's Robbie Mitchnick.

Market News
27 Aug 2026
Crypto news
View Source
Bullish
Rising US debt and deficits boost Bitcoin's appeal as a long-term investment, says BlackRock's Robbie Mitchnick.

BlackRock's Robbie Mitchnick highlights that the growing US federal debt, now over $40 trillion, and persistent fiscal deficits are renewing investor interest in Bitcoin as a long-term store of value. He argues that concerns about fiscal sustainability are more influential on Bitcoin's valuation than pending crypto market regulations. Despite Bitcoin's recent price volatility, its rise amid market stress reflects its potential as a digital alternative to traditional assets like gold. Future Bitcoin performance will depend on fiscal data, Treasury borrowing, bond yields, and market conditions rather than regulatory changes alone.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
Nvidia commits nearly $10B to boost Europe's AI, backing four German startups and partnering with German industry.

Nvidia commits nearly $10B to boost Europe's AI, backing four German startups and partnering with German industry.

Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...

Market News
Bullish
4 hours ago
Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App